The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...

UnitedHealth Group has had a tumultuous year, marred by poor performance and controversy. Eli Lilly has thrived as it's taken ...

Eli Lilly and Company (NYSE:LLY) is included among the 12 Best Long Term US Stocks to Buy Now. On December 16, Daiwa analyst ...

The average participant getting a 12-mg weekly injection lost 71 pounds in 68 weeks.  "This is beyond what we see with any ...

Retatrutide treatment resulted in significant improvements in WOMAC pain scores and body weight compared with placebo in the TRIUMPH-4 trial.

More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.

Eli Lilly's retatrutide compound mimics three hormones associated with hunger regulation. "Lilly Reports Positive Results in Next-Gen Obesity Drug Trial -- Update," at 8:27 a.m. ET on Dec. 11, ...

Eli Lilly and Company has delivered significant positive developments this week, though its shares experienced a minor pullback in Wednesday's trading sessio ...

Though it hasn't even wrapped up clinical trials, the weight loss drug retatrutide already has a cult following.

Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal ...

Science Corporation, founded by Neuralink’s first president, Max Hodak, has unveiled a prototype machine to extend the life ...

With a market capitalization approaching the $1 trillion mark, Eli Lilly is engaged in a close competitive race with Novo Nordisk for dominance in the obesity treatment sector. Market researchers ...